Prevention.  Using PrEP cost-effective in high-risk MSM groups.
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000191:economics; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D004338:Drug Combinations; D016527:Drug Costs; D000068679:Emtricitabine; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage* / Q000191:economics; D012307:Risk Factors; D000068698:Tenofovir
D019380:Anti-HIV Agents; D004338:Drug Combinations; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine